Although Ebola’s explosions are scarce, the disease is severe and often fatal, with diminutive treatment options. Instead of aiming at the virus itself, one promising therapeutic approach would be to stop proteins in the human host cell, which was the virus. However, finding these regulators of viral infection using existing methods was tough and is particularly tough for the most threatening viruses, such as ebola, which require strict biosafetic protocols with high content.
Now scientists from the Broad Institute and the National Emerging Infectious Diseases Laboratories (Neidl) at Boston University have used a screening method based on a wide range of painting to identify human genes that, after silence, impair Ebola’s virus. The method, known as an optical screening (OPS), enabled scientists to test, in about 40 million human cells revived by CRISPR, such as silencing every gene in the human genome affects the replication of the virus.
Using analyzes based on images of disturbed cells, they identified many host proteins involved in various stages of ebola infections, which after suppressing the virus ability to replicate. These viral regulators can represent the possibilities one day therapeutically intervene and reduce the severity of the disease in people already infected with the virus. This approach can be used to examine the role of various proteins during infection with other pathogens as a way to find fresh drugs for tough to treat infection.
The study appears in
“This study shows the power of OPS to examine the dependence of dangerous viruses, such as ebola on the factors of the host at all stages of the viral life cycle and research new roads to improve human health,” said co -bred author Paul Blainey, a wide main member of the department and professor in the Department of Biological Engineering in MIT.
Earlier, members of the Blainey laboratory developed Optical screening method As a way to combine the benefits of high content imaging, which can show a number of detailed changes in a gigantic number of cells simultaneously, with combined hallway screens, which show how genetic elements affect these changes. In this study, they established cooperation with the laboratory of Robert Davey in BU to apply an optical screening for Ebola virus.
The team used CRISPR to knock out every gene in the human genome, for a time, in almost 40 million human cells, and then infected each cell with an ebola virus. Then they repaired these vascular cells in laboratory vessels and inactivated them so that the remaining processing could occur outside the high content laboratory.
After taking photos of the cells, they measured the general viral protein and RNA in each cell using the software for analyzing the CellProfiller image and to get even more information from images, they turned to AI. With the assist of team members in the center of Eric and Wendy Schmidt in Broad, led by the co -author of the study and a member of the Caroline Uhler wide core department, they used a deep learning model to automatically determine the stage of Ebola infection for each single cell. The model was able to make subtle distinctions between the stages of infection in a high bandwidth way, which was not possible using previous methods.
“The work represents the deepest diving so far in how the ebola virus develops a cell to cause diseases, and the first real view on the time of this reprogramming,” said the author of BU Chobanian and Avedisian School of National National National Emerging Diseases Laboratories. “AI gave us an unprecedented ability to do it on a large scale.”
By sequencing the CRISPR guide, in all 40 million cells, scientists individually determined which human gene was silenced in each cell, indicating which host protein (and potential viral regulators) were targeted. The analysis revealed hundreds of host proteins, which after silencing changed the overall level of infection, including many required to the viral entry into the cell.
Rejection of other genes has improved the amount of virus in inclusive bodies, structures that form in a human cell to act as viral factories, and prevented further infection. Some of these human genes, such as, indicated an unrecognized role in mitochondria in the process of ebola virus infection, which can probably be used therapeutically. Indeed, the treatment of cells with a diminutive UQCRB molecular inhibitor reduced Ebola’s infection without affecting your own cell health.
Other genes, after silence, changed the balance between viral RNA and protein. For example, the disturbance of the gene called a viral RNA in relation to protein. Scientists are currently conducting further research in the laboratory to better understand the role of a belt and other proteins in Ebola infection and whether they can be targeted therapeutically.
The study approach can also be used to examine other pathogens and emerging infectious diseases and search for fresh ways of their treatment.
“Using our method, we can measure many functions simultaneously and discover new tips on the interaction between the virus and the host, in a way that is not possible thanks to other research approaches,” said the author of First Rebecca Carlson, a graduate in the Blainey and Nira Hacohen laboratories on Broad and who developed work, as well Boston.
These works were partially financed by the Broad Institute, National Human Genome Research Institute, Burroughs WellCome Fund, Fannie and John Hertz Foundation, National Science Foundation, George F. Carrier Postoktoral Fellowship, Eric and Wendy Schmidt Center in Broadt Institute, National Institutes of Health and Office of Naval Research.